Holen Sie sich die Stockscreener-App
0.6517
1.53%
-0.0101
Handel nachbörslich:
.65
-0.0017
-0.26%
Schlusskurs vom Vortag:
$0.6618
Offen:
$0.66
24-Stunden-Volumen:
141.09K
Relative Volume:
0.76
Marktkapitalisierung:
$1.00M
Einnahmen:
$743.00K
Nettoeinkommen (Verlust:
$-7.63M
KGV:
-0.2172
EPS:
-3
Netto-Cashflow:
-
1W Leistung:
-1.78%
1M Leistung:
-3.38%
6M Leistung:
-59.77%
1J Leistung:
-72.15%
1-Tages-Spanne:
$0.65
$0.6607
1-Wochen-Bereich:
$0.6311
$0.665
52-Wochen-Spanne:
$0.6301
$3.12
Can-Fite Biopharma Ltd ADR Stock (CANF) Company Profile
Firmenname
Can-Fite Biopharma Ltd ADR
Sektor
Branche
Telefon
972 3 924 1114
Adresse
10 Bareket Street, Kiryat Matalon PO Box 7537, Petah-Tikva
Vergleichen Sie CANF mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CANF
Can-Fite Biopharma Ltd ADR
|
0.6517 | 9.65M | 743.00K | -7.63M | 0 | -3.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Can-Fite Biopharma Ltd ADR Stock (CANF) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2017-08-11 | Eingeleitet | Maxim Group | Buy |
| 2016-10-19 | Fortgesetzt | ROTH Capital | Buy |
| 2016-08-29 | Fortgesetzt | Rodman & Renshaw | Buy |
| 2015-11-30 | Bestätigt | H.C. Wainwright | Buy |
| 2015-03-31 | Bestätigt | H.C. Wainwright | Buy |
| 2015-03-30 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2014-12-29 | Bestätigt | ROTH Capital | Buy |
| 2014-11-18 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Can-Fite Biopharma Ltd ADR Aktie (CANF) Neueste Nachrichten
Can-Fite BioPharma (NYSE:CANF) Given Buy Rating at D. Boral Capital - Defense World
Can swing trading help recover from Crane NXT Co. lossesMarket Growth Summary & AI Optimized Trade Strategies - Newser
Has FVRR formed a bullish divergence2025 Key Lessons & Low Risk High Win Rate Picks - Newser
Applying sector rotation models to Vale S.A. Depositary ReceiptJuly 2025 Catalysts & Reliable Price Action Trade Plans - Newser
Sentiment analysis tools applied to Vertical Aerospace Ltd.2025 Dividend Review & Weekly Setup with ROI Potential - Newser
Using RSI to spot recovery in ALDFUJuly 2025 Market Mood & Precise Swing Trade Entry Alerts - Newser
Fragrances Inc.Earnings Growth Report & Stepwise Swing Trade Plans - Newser
Full technical analysis of POST stockMarket Sentiment Summary & Breakout Confirmation Trade Signals - Newser
What indicators show strength in Enterprise Products Partners L.P. Limited PartnershipIn-Depth Stock Trading Volume Analysis - Newser
Can-Fite reaches 50% enrollment milestone in pancreatic cancer trial By Investing.com - Investing.com South Africa
Can-Fite reaches 50% enrollment milestone in pancreatic cancer trial - Investing.com
Can-Fite BioPharma prices $5 million public offering of ADSs - Investing.com
Can-Fite BioPharma prices $5 million public offering of ADSs By Investing.com - Investing.com India
Harbour Energy Begins First Oil Production From Maria Phase 2 - The Globe and Mail
Can Fite Biopharma stock hits 52-week low at $1.14 By Investing.com - Investing.com South Africa
Can Fite Biopharma stock hits 52-week low at $1.14 - Investing.com
Can Fite Biopharma stock hits 52-week low at $1.22 By Investing.com - Investing.com South Africa
Can Fite Biopharma stock hits 52-week low at $1.22 - Investing.com
Can-Fite BioPharma announces $3M registered direct offering - Investing.com
Can-Fite’s Surging Stock: Is It Time to Act? - timothysykes.com
Can Fite Biopharma stock hits 52-week low at $1.86 - Investing.com
Can-Fite's partner Vetbiolix secures $325M deal for dog arthritis drug - Investing.com
List of Israeli Stocks Traded on the NYSE Worth Considering - The Times of Israel
Can-Fite BioPharma seeks FDA nod for NASH drug trial - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Liver Cirrhosis Market to Observe Impressive Growth at a CAGR of 6.3% by 2032, Predicts DelveInsight - PR Newswire UK
Pacira's (PCRX) Q3 Earnings Miss Estimates, Revenues Beat - Yahoo Finance
Le 1001 azioni che si sono schiantate sul mercato azionario USA - Scenari Economici
bioAffinity Technologies Inc Stock Price Today | NASDAQ: BIAF Live - Investing.com
Earnings Scheduled For November 30, 2020 - Yahoo Finance
4 Penny Stocks On Robinhood To Buy Under $4 Now; Worth The Risk? - Penny Stocks
10 Biopharmaceutical Companies Trying To Cure Cancer - Yahoo Finance
Can-Fite's Rheumatoid Arthritis Drug Faces Off With Methotrexate In Phase III Trial For $40 Billion Market (NYSE:CANF) - Seeking Alpha
Finanzdaten der Can-Fite Biopharma Ltd ADR-Aktie (CANF)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):